Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1173 Results

Title
Intervention Indication Therapeutic Area Year Actions
Teplizumab for the delay of clinical type-1 diabetes in at-risk patients aged 8 years and over Teplizumab (PRV-031; MGA031) Type 1 diabetes Endocrine Nutritional and Metabolic Disorders 2022 View  |  Download
Tepotinib for advanced non-small cell lung cancer harbouring MET exon14- skipping mutations Tepotinib (MSC-2156119J; TEPMETKO) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Teprotumumab for thyroid eye disease Teprotumumab ((HZN-001; R-1507; RV 001) Thyroid eye disease (TED) Immunology 2024 View  |  Download
Tezacaftor and ivacaftor for cystic fibrosis homozygous or heterozygous for F508del mutation in patients aged 12 years and older who discontinued treatment with Orkambi Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor) Cystic fibrosis Genetic Disorders , Respiratory System 2019 View  |  Download
Tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis heterozygous for F508del mutation and one residual mutation in patients aged 6 to 11 years Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor) Cystic fibrosis Genetic Disorders , Respiratory System 2019 View  |  Download
Tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis homozygous for F508del mutation in patients aged 6 to 11 years Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor) Cystic fibrosis Genetic Disorders , Respiratory System 2019 View  |  Download
Tezepelumab for severe, uncontrolled asthma Tezepelumab (AMG 157; MEDI9929) Asthma Respiratory System 2020 View  |  Download
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps Tezepelumab (AMG 157; MEDI9929) Nasal polyps , Rhinosinusitis Ear Nose and Throat (ENT) 2023 View  |  Download
Ticagrelor for prevention of cardiovascular events in patients with type 2 diabetes mellitus who have coronary artery disease Ticagrelor (Brilique; AZD6140) Major cardiovascular events Cardiovascular System 2018 View  |  Download
Ticagrelor in addition to acetylsalicylic acid for prevention of stroke in patients with acute ischaemic stroke or transient ischaemic attack Ticagrelor (Brilique; AZD6140) Stroke Cardiovascular System 2019 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications